Dataset v2026-08-31 59 providers tracked 72% of prices verified within 7 days Every price carries a source, a date and a grade. How we verify

Price transparency, scored

The market’s favorite number is the one before the fees. This page counts who publishes the rest.

As of August 31, 2026:

Price transparency in this market is partial by design: teaser rates are universal, but 26 of 39 providers publish the maintenance-dose price and 2 of 18 multi-month plans state how they bill. Every gap is visible on this site as “not published” and caps the row’s grade at B or C — which is the incentive the market needs to publish the number.

Tirzepatide providers with a price, scored on what their own pages disclose. Gaps cap the evidence grade; they never get filled with guesses.
DisclosureShare of providers
Publishes any purchasable price39 of 39 (100%) of priced rows; 10 tracked providers publish none
Maintenance-dose price published26 of 39 (67%)
Membership fee amount published (incl. $0)22 of 39 (56%)
Shipping terms published24 of 39 (62%)
Consultation terms published22 of 39 (56%)
Dose behavior stated20 of 39 (51%)
Billing frequency stated on multi-month plans2 of 18 (11%)
Dispensing pharmacy named10 of 39 (26%)

Definitions used on this page

True month-to-monthA recurring plan requiring no multi-month commitment, priced at the maintenance dose with every mandatory recurring fee included.
All-in priceMedication plus all mandatory recurring fees (membership, provider care where billed separately) and mandatory shipping.
Grade APublic price and terms verified on the provider's own page by our editors.
Grade BPublic price verified on the provider's own page; some mandatory-fee or term details are not published.
Grade DThird-party report only; not yet recorded from the provider's own page. Never counted as verified.